It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

We recently published a list of 11 Worst-Performing Blue Chip Stocks So Far in 2025. In this article, we are going to take a ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.